Synaptic potentiation of anterior cingulate cortex contributes to chronic pain of Parkinson’s disease

Zhaoxiang Zhou1, Penghai Ye4, Xu-Hui Li1,2, Yuxiang Zhang2, Muhang Li3, Qi-Yu Chen1,2, Jing-Shan Lu1,2, Man Xue1, Yanan Li2, Weiqi Liu1, Lin Lu4, Wantong Shi1, Ping-Yi Xu4* and Min Zhuo1,2,3*

Abstract
Parkinson’s disease (PD) is a multi-system neurodegenerative disorder. Patients with PD often suffer chronic pain. In the present study, we investigated motor, sensory and emotional changes in three different PD mice models. We found that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treatment caused significant changes in all measurements. Mechanical hypersensitivity of PD model induced by MPTP peaked at 3 days and persisted for at least 14 days. Using Fos transgenic mice, we found that neurons in the anterior cingulate cortex (ACC) were activated after MPTP treatment. Inhibiting ACC by bilateral microinjection of muscimol significantly reduced mechanical hypersensitivity and anxiety-like responses. By contrast, MPTP induced motor deficit was not affected, indicating ACC activity is mostly responsible for sensory and emotional changes. We also investigated excitatory synaptic transmission and plasticity using brain slices of MPTP treated animals. While L-LTP was blocked or significantly reduced, E-LTP was not significantly affected in slices of MPTP treated animals. LTD induced by repetitive stimulation was not affected. Furthermore, we found that paired-pulse facilitation and spontaneous release of glutamate were also altered in MPTP treated animals, suggesting presynaptic enhancement of excitatory transmission in PD. Our results suggest that ACC synaptic transmission is enhanced in the animal model of PD, and cortical excitation may play important roles in PD related pain and anxiety.

Keywords: Parkinson’s disease, Chronic pain, ACC, LTP, MPTP

Introduction
Parkinson’s disease (PD) is a neurodegenerative disease classically characterized by motor dysfunction [1]. In addition to the motor symptoms, the non-motor symptoms of PD such as pain and anxiety, are gaining more clinical attention [2]. There are 30–95% of patients with PD suffering from different forms of pain, including acute pain and chronic pain [3]. More than 40% PD patients also suffer anxiety [4]. However, there is no effective clinical treatment for PD-related chronic pain and anxiety. Different animal models have been developed for the study of basic mechanism of PD, including 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated model, 6-hydroxydopamine (6-OHDA)-treated model as well as A53T transgenic mice [5, 6].

Most of previous PD basic studies mainly focused on midbrain dopaminergic neurons [7], less is known about the ACC. The anterior cingulate cortex (ACC) is a key cortical region in pain perception, chronic pain and emotional anxiety and fear [8–10]. Excitatory synaptic transmission in the ACC undergo both pre- and post-synaptic...
long-term potentiation (LTP) in different animal models of chronic pain [11–13]. Furthermore, inhibiting or blocking ACC LTPs produced significantly reduction of behavioral sensory sensitization and injury-related anxiety [9, 14]. Previous studies from human brain imaging reported that ACC functions may be affected in PD patients [15, 16]. For example, Jonas et al. reported that some PD patients showed subtle gray matter atrophy in the ACC in compared to healthy control [16]. Moreover, positron emission tomography (PET) study showed that the turnover of dopamine is affected within the ACC in patients [15, 16]. For example, Jonas et al. reported that ACC functions may be affected in PD. Control animals received the same volume of saline for 3 min before slowly retracting it to prevent reflux. 1 μl/min. After the injection the needle was left in place of the skull). 6-OHDA was injected manually at a rate of lateral from the midline, 2.9 mm beneath to the surface in the dorsal striatum (1 mm anterior to Bregma, 1.7 mm of 6-OHDA injection, 8 μg at each side) was performed after surgery, the animals were allowed to recover for 2 weeks before starting the behavioral assessment [19].

**Materials and methods**

**Animals**

Adult male mice (6 to 8 weeks) were used. C57BL/6 mice were purchased from the Experimental Animal Center of Xi’an Jiaotong University (Xi’an, China). Fos-GFP mice were obtained from The Jackson Laboratory (stock number: 014135). A53T transgenic mice were gifted by Zhao-hui Liu (Medical School of Soochow University). Mouse line was maintained on a C57/BL6 background. Animals were maintained on a 12 h light/dark cycle with food and water provided ad libitum. All procedures and handling of animals were performed with permission according to the guidelines of Xi’an Jiaotong University.

**MPTP treatment**

Mice were injected intraperitoneally (i.p.) with MPTP (20 mg/kg) or sterile saline solution (four times at 2 h intervals) [18].

**6-OHDA injection**

Under anesthesia by inhalation of isoflurane (1–3%), the animals were placed on a stereotaxic frame. Bilateral injections of 6-OHDA (4 μL of a 2 μg/μl in 0.2% ascorbic acid saline solution; each animal received a total of 16 μg of 6-OHDA injection, 8 μg at each side) was performed in the dorsal striatum (1 mm anterior to Bregma, 1.7 mm lateral from the midline, 2.9 mm beneath to the surface of the skull). 6-OHDA was injected manually at a rate of 1 μl/min. After the injection the needle was left in place for 3 min before slowly retracting it to prevent reflux. Control animals received the same volume of saline according to the same procedure. After surgery, the animals were allowed to recover for 2 weeks before starting the behavioral assessment [19].

**Microinjection into the ACC**

Under anesthesia by inhalation of isoflurane (1–3%), 25-gauge guide cannulas were implanted bilaterally into the ACC (0.9 mm anterior to Bregma, 0.5 mm lateral from the midline, 1.4 mm beneath to the surface of the skull). Mice were given at least 2 weeks for recovery after cannula implantation. 30-gauge injection cannula was 0.8 mm lower than the guide. For intra-ACC infusion, 0.5 μl muscimol (1 μg/μl) or saline was delivered bilaterally within 90 s using a pump [20].

**Mechanical withdrawal threshold measurement**

Mice were individually placed in a round, transparent container 20 cm in diameter and were allowed to acclimate for 30 min before testing. The mice paw withdrawal threshold was tested with von Frey filaments (Stoelting; Wood Dale, Illinois) applied to the paw. The animals were placed in Lucite cubicles over a wire mesh and acclimated for 30 min before testing. A series of filaments (0.008, 0.02, 0.04, 0.16, 0.4, 0.6, 1, 1.4, 2 g) with various bending forces (according to 0.078, 0.196, 0.392, 1.568, 3.92, 5.88, 9.8, 13.72, 19.6 mN) were applied to the plantar surface of the hindpaw until the mice withdrew from the stimulus. Each filament was applied twice. The lowest force at which a withdrawal response was obtained was then taken as the paw withdrawal threshold [13].

**Mechanical alldynia test**

Mice were individually placed in a round, transparent container 20 cm in diameter and were allowed to acclimate for 30 min before testing. Mechanical sensitivity was assessed with a set of von Frey filaments. Based on preliminary experiments that characterized the threshold stimulus in untreated animals, the innocuous 0.04 g filament was used to detect mechanical alldynia. The filament was applied to the point of bending six times to the surfaces of the hindpaws. Positive responses consisted of prolonged hindpaw withdrawal followed by licking or scratching. Mechanical threshold was assessed on the basis of the responsiveness of the hindpaw to the application of von Frey filaments to the point of bending. The filament was applied over the dorsum of the paw while the animal was resting.

**Hot plate test**

The mice were placed in the behavior room at least 0.5 h before the test to allow them to become accustomed to the experimental apparatus. The mouse was placed on the hot (55 °C) plate and the latency to their first reaction...
(licking, shaking, jumping, or lifting of the hind paw) was recorded manually. If the mouse did not show any response within 20 s, the test was terminated to avoid tissue damage and the latency to the response was recorded as 20 s. Three values were used for average of latency to response.

Tail flick test
The spinal nociceptive tail-flick reflex was evoked by focused, radiant heat provided by a 50 W projector lamp focused on a 1.5 mm by 10 mm area on the underside of the tail. The latency to reflexive removal of the tail from the heat was measured by a digital photocell timer to the nearest 0.1 s. The cutoff time of 10 s was used to minimize damage to the skin of the tail.

Open-field test
To record locomotor activity, we used an open-field activity monitor (40 cm by 40 cm by 30.5 cm). This system uses paired sets of photo beams to detect movement in the open field, and movement is recorded as beam breaks. The open field is placed inside an isolation chamber with dim illumination and a fan. Locomotor activity was then measured for 30 min (20 cm * 20 cm for center zone, 40 cm * 40 cm for peripheral zone).

Elevated plus maze
The elevated plus maze (EPM) consisted of two open arms and two closed arms situated perpendicular to each other. The maze was situated ~ 70 cm from the floor. For each test, mice were individually placed in the center square and allowed to move freely for 5 min. The number of entries and time spent in each arm were recorded. A video camera tracking system was used to generate the traces.

Grip-strength test
The grip-strength apparatus is comprised of a wire grid connected to an isometric force transducer (dynamometer). In the grip-strength test, mice were held by their tails and allowed to grasp the grid with their forepaws. The mice were then gently pulled backward by the tail until the grid was released. The maximal force exerted by the mouse before losing grip was recorded. The mean of three measurements for each animal was calculated.

RotaRod test
To test motor function, we used a RotaRod. The RotaRod test was performed by measuring the time each animal was able to maintain its balance while walking on a rotating drum. 1 h before testing, animals were trained on the RotaRod at a constant acceleration of 16 rpm until they could stay on for 30 s. For testing, the RotaRod was set to accelerate from 4 to 40 rpm over a 5 min period. Mice were given three trials with a maximum time of 300 s and a 5 min inter-trial rest interval. The latency to fall was taken as a measure of motor function.

Homecage behaviors
24 h homecage behaviors were tested using AI homecage system (Shanghai Vanbi Intelligent Technology Co., Ltd.). The digital video cameras were mounted perpendicular to the cages. The cameras input into a Pelco video processor connected to computers. Video data were analyzed by Tracking Master software (Shanghai Vanbi Intelligent Technology Co., Ltd.). Activity time, standing time and hanging time were recorded and analyzed. During 24 h recording, mice were housed in standard cages on a 12 h light/dark cycle with food and water provided ad libitum [21].

Immunohistochemistry
Mice were anaesthetized with isoflurane and perfused transcardially with PBS, followed by 4% paraformaldehyde in PBS. Brains were extracted from the skulls and incubated in 4% PFA at room temperature overnight. The brains were then removed, and postfixed in the same fixative for 4 h before cryoprotection in PBS containing 30% sucrose overnight at 4 °C. Brains were transferred to PBS and 30 µm coronal slices were taken using a vibratome and collected in PBS.

Cell counting
Fluorescent images were acquired using light microscope (SLIDEVIEW VS200, Olympus, Tokyo, Japan) at the 20X objective. The laser with a wavelength of 488 nm was used for GFP excitation and 358 nm was used for DAPI. The number of Fos-GFP-positive, and DAPI-positive cells in a set region of interest (ROI) were quantified manually with ImageJ (https://imagej.nih.gov/ij/). The size of the ROI was standardized across brains, animals, experiments, and groups. All cell counting experiments were conducted blind to experimental group. To calculate the percentage of overlapping cells we counted the number Fos-GFP-positive cells and divided by the total number of DAPI-positive cells.

Field potential recordings
Slice preparation
The general methods for preparing ACC slices were similar to those described previously [22]. Adult male mice were anesthetized by inhalation of isoflurane (1%-3%), and the whole brain was quickly removed from the skull and submerged in ice-cold oxygenated (95% O₂ and 5% CO₂) artificial cerebrospinal fluid (ACSF) containing the following (in mM): 124 NaCl, 4.4 KCl, 2 CaCl₂,
1 MgSO$_4$, 25 NaHCO$_3$, 1 NaH$_2$PO$_4$, and 10 glucose, pH 7.35–7.45. After cooling in the ACSF for a short time, the whole brain was trimmed to yield an appropriate sample to glue onto the ice-cold stage of a vibrating tissue slicer (VT1200S, Leica). Coronal brain slices (300 µm), containing the ACC, were prepared after the corpus callosum connection. After cutting, slices were then incubated in a submerged recovery chamber with the ACSF, for at least 2 h at room temperature.

**Preparation of the multi-electrode array**
The MED64 recording system (Panasonic, Japan) was used for extracellular field potential recordings. There is an array of 64 planar microelectrodes in the MED64 probe (P515A, Panasonic, Japan), arranged in an 8 × 8 pattern, with an interpolar distance of 150 µm. The surface of the MED64 probe was treated with 0.1% polyethyleneimine in 25 mmol/L borate buffer (pH 8.4) overnight at room temperature before experiments. Then the surface of probe was rinsed three times with sterile distilled water [22, 23].

**Electrophysiological recordings**
After incubation, one slice containing the ACC was transferred to the prepared MED64 probe and perfused with oxygenated (95% O$_2$ and 5% CO$_2$) ACSF at 28–30 °C and maintained at a 2 ml/min flow rate. The slice was positioned on the MED64 probe in such a way that the different layers of the ACC were entirely covered by the whole array of the electrodes, and then a fine-mesh anchor was placed on the slice to ensure its stabilization during the experiments. One of the channels located in the layer V of the ACC was chosen as the stimulation site, during the experiments. One of the channels located in the ACC, were prepared after the corpus callosum connection. After cutting, slices were then incubated in a submerged recovery chamber with the ACC, for at least 2 h at room temperature.

**In vitro whole-cell patch-clamp recording**
Experiments were performed in a recording chamber by using an Olympus BX51WI microscope with infrared DIC optics for the visualization of whole-cell patch clamp recording. In the present study, Evoked EPSCs (eEPSCs) were recorded from the layer II/III neurons with an Axopatch 200B amplifier (Molecular Devices, CA), and the stimulations were delivered by a bipolar tungsten stimulating electrode placed in the layer V/V1 of the ACC slices. Control test pulses were given every 30 s. The amplitudes of eEPSCs were adjusted to between 50 and 100 pA to obtain a baseline. Paired pulse stimulations with a 50 ms interpulse interval were given during the recordings. Stable baseline recordings of eEPSCs were obtained for 10 min before the induction of the LTP protocol. The recording pipettes (pyramidal neurons, 3–5 MΩ) were filled with a solution containing 145 mM K-gluconate, 5 mM NaCl, 1 mM MgCl$_2$, 0.2 mM EGTA, 10 mM HEPES, 2 mM Mg-ATP, and 0.1 mM Na$_2$-GTP (adjusted to pH 7.2 with KOH). Spontaneous EPSCs (sEPSCs) were recorded with the K-gluconate internal solution and holding − 60 mV. Picrotoxin (100 µM) was always present to block GABA$_A$ receptor-mediated inhibitory synaptic currents in all experiments [24].

**Statistical analysis**
Results were expressed as mean ± SEM. Statistical comparisons were performed with one-way ANOVA or two-way ANOVA and Student’s t test. In all cases, *p < 0.05 was considered statistically significant.

**Results**

**PD models induced by MPTP, 6-OHDA, and A53T transgenic mice**
Since the main symptoms of PD are motor deficits, we performed the RotaRod test, grip strength test, homecage behavior recording, and open field test, which are commonly used to confirm the phenotypes of PD model animals. The behavior tests data was listed in Table 1. Motor function was assessed by RotaRod test, grip strength test, and open field test, which significantly declined after MPTP or 6-OHDA administration, but not in A53T transgenic mice (Fig. 1a–d). Moreover, in the homecage behavior test, only MPTP-treated mice showed reduced activity time (Fig. 1e). Standing time and hanging time were decreased in MPTP-treated and 6-OHDA-treated mice (Fig. 1f, g). A53T transgenic mice showed decreased hanging time, but...
not standing time (Fig. 1f, g). These results showed MPTP or 6-OHDA administration impaired the motor function of mice, including muscle capacity, the coordination of movement, and homecage behaviors.

Next, we performed EPM (Fig. 2e) and open field tests (Fig. 2h) to assess the anxiety behaviors in three PD models. Decreased time spent in open arms and distance in center area indicated that MPTP-treated and 6-OHDA-treated mice exhibited increased anxiety-related behaviors (Fig. 2f, i). However, there was no difference in time spent in open arms and time in center area between A53T transgenic mice and wildtype mice in the EPM and open field test (Fig. 2f, i). Taken together, these results indicate that the MPTP and 6-OHDA administration induces motor deficits and increased anxiety-related behaviors.

Pain hypersensitivity
Chronic pain is the most prominent non-motor symptom in patients with Parkinson’s disease [26]. Therefore, we used several nociceptive behavioral tests to measure the mechanical allodynia, threshold, and thermal hyperalgesia. The behavior tests results were listed in Table 1. Compared to WT or saline group mice, the mice of three PD models exhibited reduced mechanical threshold and increased responses in mechanical allodynia test (Fig. 2a, b). In the thermal pain tests, A53T transgenic mice also showed reduced response time than saline-treated mice in tail flick test, but not in hot plate test (Fig. 2c, d), and 6-OHDA-treated mice showed reduced response time than saline-treated mice in tail flick test, but not in hot plate test (Fig. 2c, d). However, MPTP-treated mice exhibited reduced response time in the both thermal threshold tests (Fig. 2c, d). Taken together, these three common PD models exhibited varying degrees of pain hypersensitivity. MPTP-treated mice model was used in next experiments. The pain hypersensitivity in MPTP-treated mice peaked at 3d and existed until 14d (Fig. 3a).

Table 1 Behavior test results of motor function, pain, and anxiety-related behavior in A53T transgenic, MPTP, and 6-OHDA mice models used for the study of Parkinson’s disease

| Behavior tests                                | A53T transgenic model | MPTP model | 6-OHDA model |
|----------------------------------------------|-----------------------|------------|--------------|
| Motor function tests                         |                       |            |              |
| Grip strength (kg)                            | 0.22 ± 0.01           | 0.20 ± 0.01| 0.20 ± 0.008 |
| RotaRod (min)                                | 4.34 ± 0.45           | 3.90 ± 0.39| 4.06 ± 0.37 |
| Open field                                   | 74.32 ± 4.10          | 79.22 ± 9.23| 73.63 ± 6.46 |
| -Total distance (m)                          | 80.88 ± 8.46          | 51.66 ± 7.41| 47.23 ± 4.10 |
| Al homecame                                  | 14.56 ± 2.63          | 13.66 ± 1.54| 12.72 ± 1.56 |
| -Hanging time (min)                          | 10.41 ± 2.02          | 9.11 ± 1.38 | 9.54 ± 0.90 |
| Al homecame                                  | 10.82 ± 3.37          | 10.46 ± 2.54| 10.07 ± 2.02 |
| -Standing time (min)                         | 12.80 ± 4.14          | 7.01 ± 3.22 | 6.48 ± 3.11 |
| Al homecame                                  | 39.65 ± 6.20          | 38.69 ± 3.30| 36.69 ± 2.37 |
| -Activity time (%)                           | 42.37 ± 4.58          | 15.36 ± 5.73| 35.36 ± 4.89 |
| Pain behavior tests                          |                       |            |              |
| Tail flick (s)                                | 5.60 ± 0.37           | 6.02 ± 0.26| 5.54 ± 0.46 |
| Hot plate (s)                                 | 5.00 ± 0.51           | 4.23 ± 0.19| 4.20 ± 0.12 |
| Mechanical threshold (g)                     | 12.04 ± 1.09          | 12.48 ± 0.96| 11.56 ± 0.81 |
| Mechanical alldynia (%)                      | 10.09 ± 0.65          | 10.08 ± 0.46| 10.10 ± 0.84 |
| Anxity-related behavior tests                |                       |            |              |
| Open field                                   | 0.73 ± 0.15           | 0.84 ± 0.14| 0.76 ± 0.18 |
| -Time in central zone (%)                    | 0.49 ± 0.11           | 0.28 ± 0.05| 0.37 ± 0.10 |
| Mechanical alldynia (%)                      | 5.00 ± 4.14           | 3.5 ± 6.31 | 6.67 ± 3.40 |
| Elevated plus maze                           | 35.00 ± 9.69          | 47.5 ± 12.08| 40.00 ± 18.76|
| -Time in open arms (%)                       |                        |            |              |
| Elevated plus maze                           | 11.34 ± 3.20          | 12.94 ± 2.30| 11.67 ± 2.37 |
| -Number of entries                           | 16.04 ± 2.09          | 11.89 ± 0.86| 9.67 ± 0.91 |
| Increased pain (s)                           | 11.94 ± 1.65          | 4.59 ± 0.66 | 5.76 ± 0.64 |
| Elevated plus maze                           | 16.25 ± 4.20          | 15.64 ± 3.30| 13.37 ± 2.37 |
| -Number of entries                           | 14.65 ± 4.58          | 12.96 ± 6.73| 11.38 ± 4.89 |

N.S.: not significant, ↓: decreased, ↑: increased
**p < 0.01
Activation of ACC in MPTP induced PD model

The ACC is well known to be a critical region in sensory perception, especially in chronic pain [9]. However, whether ACC is involved in PD-related chronic pain remains unknown. To determine the role of the ACC in PD-related chronic pain, we utilized Fos-GFP mice that express the GFP in behaviorally activated Fos-expressing neurons, to assess the distribution of activated neurons in MPTP-treated PD mice. It has been shown that Fos could be used as a marker for neuronal activation...
Fig. 2 Pain and anxiety symptoms assessment of three PD mice models. 

- **Mechanical threshold test**: 
  - **Mechanical threshold were reduced** (a) and mechanical allodynia were increased (b) in all three PD models. Response latency in hot plate test was reduced in A53T transgenic and MPTP-treated mice (c). MPTP-treated and 6-OHDA-treated mice exhibited shorter response latency in tail flick test (d).

- **Representative traces showing** the movement of mice in EPM (e) and open field test (h). MPTP-treated and 6-OHDA-treated mice exhibited increased anxiety-related behaviors in EPM (f) and open field test (i), and there was no significant difference of entry number in EPM (g).

In hot plate test, tail flick test, open field test and EPM, n = 12 in WT and A53T groups, n = 13 in saline and MPTP groups, n = 12 in saline and 6-OHDA groups. In mechanical threshold test, n = 6 in WT and A53T groups, n = 6 in saline and MPTP groups, n = 6 in saline and 6-OHDA groups. In mechanical allodynia test, n = 6 in WT and A53T groups, n = 7 in saline and MPTP groups, n = 6 in saline and 6-OHDA groups.
following sexual stimulations [20]. To quantify neuronal activation in the ACC by PD-related chronic pain, we counted activated neurons (Fos-positive) and total neurons (DAPI-positive) in the ACC (Fig. 3a, b). We found that the number of activated neurons and double labeling percentage were significantly enhanced at 3 days after injection of MPTP (Fig. 3c–e).

**Inhibition of ACC reduces pain hypersensitivity and anxiety but not motor responses**

Previous results found that ACC neurons were activated and the excitability of ACC neurons was enhanced in nerve injury mice [12, 27]. Therefore, we then performed pharmacological manipulations to see if the activation of the ACC is necessary to affect the behaviors in MPTP-induced PD mice (Fig. 3f). It is known that local injection of muscimol, a selective agonist for GABA<sub>A</sub> receptors, could inactivate the ACC neuronal activity [20]. We found that bilateral injections of muscimol (0.5 μl per side) into the ACC of MPTP-treated mice significantly reduced mechanical allodynia and increased mechanical threshold (Fig. 3g, h). In grip strength and RotaRod tests, there was no difference between injection of muscimol and saline (Fig. 5i, j). Compared to saline group, both the total distance in open field tests (Fig. 3k–o). However, the total distance in open field test was increased (Fig. 3n).

**ACC LTP is occluded in MPTP-treated mice**

Increasing evidence suggests that LTP and LTD in the ACC are causally related to chronic pain [8, 28]. Thus, we next investigated the LTP and LTD in the ACC using saline-treated and MPTP-treated mice. A 64-channel multielectrode array recording system (MED64) was used to record LTP and LTD in the ACC. We placed a slice containing the ACC on the MED64 chamber and ensured the recording microelectrodes covered the ACC area (Fig. 4a, b). One channel located in the deep layer of ACC was chosen as the stimulation site.

The fEPSP slopes of all activated channels were recorded from superficial to deep layer around the stimulation site for 0.5 h min as a baseline (Fig. 4c). After recording stable baseline for 0.5 h, we applied TBS to evoke network LTP in the ACC. In the ACC of saline-treated mice, TBS induced late-phase LTP (L-LTP) in most of the active channels, which was similar to our previous reports [23]. In one typical slice of saline-treated mice, the final averaged slope of all 8 channels from the slice was 128.9 ± 8.9% of the baseline at 3 h after applying TBS (Fig. 4d). In all 103 activated channels that recorded from 11 slices of 7 saline-treated mice, we found that there were 52 channels with L-LTP, 28 channels with E-LTP and 23 channels showed none-LTP (Fig. 4i). The final averaged fEPSP slope of all activated channels was 125.5 ± 6.8% of the baseline at 3 h in saline-treated mice and the final averaged fEPSP slope of all channels with L-LTP was 139.5 ± 2.9% of the baseline at 3 h (Fig. 4k).

Unlike the saline-treated mice (Fig. 4c, d), TBS failed to induce LTP in most of the active channels in the MPTP-treated mice (Fig. 4e). In one typical slice of MPTP-treated 3d mice, the final averaged slope of all 11 channels from the slice was 104.0 ± 10.4% of the baseline at 3 h after applying TBS (Fig. 4f). In all 118 activated channels that we recorded from 12 slices from 7 MPTP-treated 3d mice, we found that there were 16 channels with L-LTP, 36 channels with E-LTP and 66 channels showed none-LTP (Fig. 4i). The final averaged fEPSP slope of all activated channels was 106.6 ± 6.7% of the baseline at 3 h in MPTP-treated 3d mice (Fig. 4k).

However, after MPTP injection 14d, TBS successfully induced L-LTP in most of the active channels. In one typical slice of MPTP-treated 14d mice, the final averaged slope of all 10 channels from the slice was 125.4 ± 8.6% of the baseline at 3 h after applying TBS (Fig. 4g, h). In all 97 activated channels that we recorded from 10 slices from 6 MPTP-treated 14d mice, we found that there were 48 channels with L-LTP, 21 channels with E-LTP and 28 channels showed none-LTP (Fig. 4i). The final averaged fEPSP slope of all activated channels was 124.9 ± 6.8%
Fig. 3 (See legend on previous page.)
of the baseline at 3 h in MPTP-treated 14d mice and the final averaged fEPSP slope of all channels with L-LTP was 140.5 ± 4.2% of the baseline at 3 h (Fig. 4k). The temporal changes of the averaged fEPSP slopes of all slices from three groups were showed in Fig. 4j.

Further analysis of the number of channels with L-LTP, E-LTP and none-LTP respectively showed that there were 3.9 ± 0.7 channels with L-LTP, 2.5 ± 0.4 channels with E-LTP, and 2.1 ± 0.6 channels with none-LTP in each slice of saline-treated mice on average (Fig. 4l). In MPTP-treated 3d mice, there were 1.3 ± 0.9 channels with L-LTP, 3 ± 0.6 channels with E-LTP and 5.5 ± 0.9 channels with none-LTP in each slice on average (Fig. 4l). And there were 3.9 ± 1.1 channels with L-LTP, 2.1 ± 0.5 channels with E-LTP and 2.8 ± 0.6 channels with none-LTP in each slice of MPTP-treated 14d mice on average (Fig. 4l). There was no statistical difference in the number of different types of total channels among saline-treated, MPTP-treated 3d and MPTP-treated 14d mice (Fig. 4l). However, the number of channels with L-LTP was significantly reduced in MPTP-treated 3d mice, but not MPTP-treated 14d mice (Fig. 4l). The number of channels with none-LTP was increased in MPTP-treated 3d mice, but not MPTP-treated 14d mice (Fig. 4l). These results indicate that the induction of LTP in ACC were occluded in most channels in MPTP-treated mice.

Recruitment of synaptic responses is blocked in MPTP-treated mice

Previous studies showed that some silent responses were recruited after L-LTP induction [22, 23]. To test the effect of MPTP injection on the network recruitment in the ACC, we analyzed all recruited channels from saline-treated, MPTP-treated 3d, and MPTP-treated 14d mice. We found that TBS cannot induce channel recruitment in MPTP-treated 3d mice (Fig. 5b). The time course of the recruitment changes in three groups were shown in Fig. 5e. The number of recruited channels of saline-treated and MPTP-treated 14d mice gradually increased across the extended time scale after TBS induction, but not in MPTP-treated 3d mice. These results indicate that few channels were recruited after TBS in MPTP-treated mice.

LTD in ACC is not affected in MPTP-treated mice

To explore the effect of MPTP injection on LTD in ACC, we recorded the fEPSPs baseline of all activated channels for 30 min before LTD inducing protocol was applied (LFS: 1 Hz, 900 pulses, with the same intensity as baseline recording). As shown in Fig. 6a–d, we got two different types of synaptic plasticity in all activated channels: channels with a slope decrease of more than 20% at 60 min represented LTD and channels that the fEPSP slope did not change after LFS represented none-LTD (Fig. 6c).

In a typical sample slice of a saline-treated mouse, there were 11 channels being activated, the final averaged slope of all 11 channels was 78.3 ± 6.6% of the baseline at 60 min after applying LFS (Fig. 6a, b). In a typical sample slice of a MPTP-treated 3d mouse, the final averaged slope of all 11 channels was 77.8 ± 7.1% of the baseline at 60 min after applying LFS (Fig. 6c, d). Next, we compared the final averaged slope of LTD in saline-treated and MPTP-treated 3d mice. There were 74 activated channels from 10 slices of 6 saline-treated mice and 71 activated channels from 11 slices of 6 MPTP-treated mice respectively (Fig. 6e). There was no difference in the final averaged slope of activated channels with LTD and all channels between MPTP-treated and saline-treated mice after applying LFS on stimulation site (Fig. 6f, g).
Fig. 4 (See legend on previous page.)
results suggested that intraperitoneal administration of MPTP didn’t affect LTD induced by LFS in the ACC.

There are hypotheses indicate that functional synapses can be transformed into silent synapses by endocytosis and inactivation of postsynaptic membrane α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor [29, 30]. In the present study, we found that some of active channels became silent after LFS (Fig. 7a, b). At 30 min after LFS, the amplitudes of the channels that were activated during baseline were decreased to about 0 μV (Fig. 7c). Next, we compared the number of silent channels that appeared after LFS in the ACC between saline-treated and MPTP-treated mice. There were 3.3 ± 1.5 silent channels in each slice of saline-treated mice on average and this result was similar to that in MPTP-treated mice (3.3 ± 0.8 silent channels, Fig. 7d). These results indicate that the transform of activated synapses to silent ones was not affected in MPTP-treated mice.

**Enhanced presynaptic transmission in the ACC in MPTP-treated mice**

To examine whether presynaptic mechanism is altered in the ACC of PD mice model, paired-pulse facilitation (PPF) was examined in ACC neurons in the present study. PPF is a transient form of plasticity commonly used as a measure of presynaptic function, in which the response to the second stimulus is enhanced as a result of residual calcium in the presynaptic terminal after the first stimulus. After MPTP treatment, there was a significant reduction in PPF in ACC neurons (n = 12 neurons/5 mice) compared with those from control mice (n = 10 neurons/4 mice) (Fig. 8a, b).
To further determine whether decreased PPF in the ACC in PD conditioning might be attributable to the increased presynaptic transmitter release probability, we recorded spontaneous EPSCs (sEPSCs) in ACC neurons. After MPTP treatment, there was an obvious increase of sEPSC frequency in ACC neurons compared with that of control group (saline: $1.8 \pm 0.2$ Hz, $n=9$ neurons/4 mice; MPTP: $4.1 \pm 1.1$ Hz, $n=10$ neurons/5 mice) (Fig. 2a–c). Furthermore, there was significant difference in the amplitude of sEPSCs between the two groups (saline: $6.5 \pm 0.2$ pA, $n=9$ neurons/4 mice; MPTP: $8.9 \pm 0.6$ pA, $n=10$ neurons/5 mice) (Fig. 8d, e). Together, these results indicate that the presynaptic transmission is enhanced in the ACC of MPTP-treated mice.

**Discussion**

The present study, for the first time, revealed that the ACC is involved in PD-induced chronic pain in mice model. We found that ACC activation is required for chronic pain and anxiety symptoms in the animal model of PD, but not motor function. Moreover, LTP in ACC is occluded, and presynaptic neurotransmitter release is enhanced in MPTP-treated mice, suggesting long-term...
enhancement of both presynaptic and postsynaptic functions.

Chronic pain symptom in different PD models
In our studies, we have used three PD models to offer insight into chronic pain in PD. In previous reports, MPTP-treated mice showed remarkably shorter nociceptive response latencies [31], and 6-OHDA-treated rats also exhibit reduced nociceptive thresholds [32]. Our results confirmed that MPTP-treated and 6-OHDA-treated mice models exhibited motor deficit and mechanical pain hypersensitivity. However, in thermal hyperalgesia tests, 6-OHDA-treated mice only showed decreased response latency in tail flick test, but not in hot plate test. Previous study observed thermal hyperalgesia in 6-OHDA-treated mice by using paw withdrawal latency to a radiant heat source [32]. This discrepancy might be attributable to the different methods used to test thermal pain threshold. The different methods to induce 6-OHDA model may also contribute to the difference of results. The normal or enhanced motor function in A53T transgenic model is pointed in previous studies [6, 33], but few study showed the pain hypersensitivity, which was observed in this study. The anxiety symptom in MPTP-treated and 6-OHDA-treated mice models is also consistent with previous studies [34, 35]. Besides obvious motor deficit, chronic pain and anxiety symptoms, we chose MPTP model in subsequent experiments since this model has specific advantages: (1) MPTP is the only known neurotoxin capable of causing degeneration of dopaminergic neurons in PD patients. (2) The injection of MPTP does not require any particular equipment or technical skills. (3) Systemic injection of MPTP produces a reliable and reproducible lesion of the nigrostriatal dopaminergic pathway. Therefore, MPTP-induced PD model is an appropriate model to understand the pain and anxiety symptoms study of PD patients.

ACC is responsible for chronic pain and anxiety in PD
In this report, we found that ACC is activated bilaterally in MPTP-treated mice. By local infusion of muscimol, we found that inactivation of the ACC reversed the chronic pain and anxiety symptoms in PD, suggesting that ACC activity at least partially contribute to chronic pain and emotional anxiety in PD. Furthermore, we found that the motor impairment in MPTP-treated mice was not affected by ACC microinjection of muscimol, indicating that ACC is relatively selective involved in sensory and emotional functions.

Synaptic plasticity in PD
LTP and LTD are two forms of synaptic plasticity that have been widely studied in learning and memory [36]. LTP is reported to be a key cellular model for cortical
excitation in chronic pain [8, 9]. Our data suggest that the LTP in ACC was occluded during the persistent pain in PD model. It is similar with a synaptic plasticity study of nerve injury mice, which exhibited occlusion of LTP in ACC [13]. In the prefrontal cortex (PFC) of human patients and animal models of PD, LTP is also occluded [37, 38]. Another key finding is that the recruitment of cortical circuitry by LTP was also impaired.
MPTP-treated mice. In saline-treated mice, TBS induced recruitment of silent synapses in ACC, consistent with our previous studies [22]. However, there was few recruited channels in MPTP-treated mice, because LTP in ACC was occluded by enhanced pain responses. After MPTP-treated 14d, the recruitment responses recovered with the disappearance of LTP occlusion. These results strongly indicate that excitatory transmission in the ACC is potentiated in MPTP-treated mice. As another form of synaptic plasticity, LTD in ACC has been reported to be affected in chronic pain [28, 39, 40]. Wei et al. reported that amputation caused a loss of LTD in ACC that persisted for at least 2 weeks [40]. In this study, the unaltered LTD suggested that LTD in ACC is not involved in chronic pain in PD mice. Presynaptic synaptic plasticity has been identified as playing an important role in chronic pain and anxiety [12, 14, 25, 27]. Therefore, the presynaptic enhancement of neurotransmitter release in the ACC may contribute to the chronic pain and anxiety in mice of PD model.

Potential drug target
Taken together, the presynaptic and postsynaptic excitatory transmission of ACC neurons are enhanced in MPTP-treated mice. The results are similar to ACC plastic changes reported in previous studies of chronic pain [12, 27]. As a novel target for chronic pain, adenylyl cyclase 1 (AC1) is essential for the presynaptic enhancement of glutamate release and the postsynaptic potentiation [12, 41]. Moreover, the AC1 inhibitor, NB001, produces powerful analgesic effects in different animal models of chronic pain [21, 42]. Our current findings strongly suggest that the AC1 inhibitor NB001 maybe used for the future treatment of chronic pain in PD patients.

Conclusion
In summary, our results demonstrate that ACC plays an important role in PD related pain and anxiety, but not motor function. The discovery may help to understand the chronic pain symptom in PD. Further studies would investigate the cellular and synaptic mechanisms of PD-related chronic pain.

Abbreviations
MPTP: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 6-OHDA: 6-Hydroxydopamine; ACC: Anterior cingulate cortex; PD: Parkinson’s disease; LTP: Long-term potentiation; L-LTP: Late phase LTP; E-LTP: Early phase LTP; LTD: Long-term depression; EPM: Elevated plus maze; ACSF: Artificial cerebrospinal fluid; AMPA: α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; AC1: Adenylyl cyclase 1.

Acknowledgements
The authors would like to thank Xiu-Xiu Duan and Yong-Min Liu for their contributions to this study. Thanks to Zhao-Hui Liu for providing A3T transgenic mice.

Authors’ contributions
Z.Z., PY, LL. and YZ, performed behavioral experiments and analyzed the data. ML. and WS. performed cell counting experiments. Z.Z., QYC, YL, MX. and WL. performed MED64 experiments and analyzed the data. Z.Z., JS.L, QYC., and X.H.L. drafted the manuscript and finished the final version of the manuscript. M.Z. and PYX designed the experiments, discussed, and finished the final version of the paper. All authors read and approved the final manuscript.

Funding
M.Z. is in part supported by grants from the Canadian Institute for Health Research (CIHR) project grants (PJT-148648 and 419286). X.H.L. is supported by grants from the China Postdoctoral Science Foundation (2019M663669) and Basic Research Program of Natural Science in Shaanxi Province (2020JQ-085). This work was also supported by research grants from National Key R&D Program of China (2016YFC1306601, 2017YFC1310300), National Natural Science Foundation of China (82071416, 81870992, 81870856), a technology project of Guangzhou (2018–1202-SF-0019, 2019ZD0D09).

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
Experiments were performed in Xi’an, and Research protocols have been approved by the Ethics Committee of Xi’an Jiaotong University.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Center for Neuron and Disease, Frontier Institutes of Science and Technology, Xi’an Jiaotong University, Xi’an 710049, China. 2 Institute of Brain Research, Qingdao International Academician Park, Qingdao, Shandong, China. 3 Department of Physiology, Faculty of Medicine, University of Toronto, Medical Science Building, 1 King’s College Circle, Toronto, ON M5S 1A8, Canada. 4 Department of Neurology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 5 Department of Life Sciences, Graduate School of Arts and Sciences, University of Tokyo, Tokyo, Japan.

Received: 10 August 2021 Accepted: 18 October 2021 Published: 6 November 2021

References
1. Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39:889–909.
2. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464–74.
3. Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA J Am Med Assoc. 2020;323(6):548.
4. Starkstein SE, Robinson RG, Leiguarda R, Preziosi TJ. Anxiety and depression in Parkinson’s disease. Behav Neurol. 2015;6(3):151.
5. Buhidma Y, Rukavina K, Chaudhuri KR, Duty S. Potential of animal models for advancing the understanding and treatment of pain in Parkinson’s disease. NPJ Parkinson’s Dis. 2020;6:1.
6. Paumier KL, Sukoff Rizzo SJ, Berger Z, Chen Y, Gonzales C, Kaftan E, et al. Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson’s disease. PLoS ONE. 2013;8(8): e70274.

7. Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet. 2009;373(9680):655–65.

8. Zhou M. Cortical excitation and chronic pain. Trends Neurosci. 2008;31(4):199–207.

9. Bliss TV, Collingridge GL, Kaang BK, Zhuo M. Synaptic plasticity in the anterior cingulate cortex in acute and chronic pain. Nat Rev Neurosci. 2016;17(8):485–96.

10. Vogt BA. Pain and emotion interactions in subregions of the cingulate gyrus. Nat Rev Neurosci. 2005;6(7):533–44.

11. Zhuo M. Long-term potentiation in the anterior cingulate cortex and chronic pain. Philos Trans R Soc Lond B Biol Sci. 2014;369(1633):20130146.

12. Zhao MG, Ko SW, Wu LJ, Toyoda H, Xu H, Quan J, et al. Enhanced presynaptic neurotransmitter release in the anterior cingulate cortex of mice with chronic pain. J Neurosci. 2006;26(35):8923–30.

13. Song Q, Zheng HW, Li XH, Huganir RL, Kuner T, Zhuo M, et al. Enhanced synaptic plasticity in the anterior cingulate cortex. Science. 2010;330(6009):1400–4.

14. Koga K, Dascalzi G, Chen T, Ko H-G, Lu J, Li S, et al. Coexistence of two forms of LTD in ACC provides a synaptic mechanism for the interactions between anxiety and chronic pain. Neuron. 2015;85(2):377–89.

15. Gallagher CL, Bell B, Palotti M, Oh J, Christian BT, Okonkwo O, et al. Anterior cingulate dopamine turnover and behavior change in Parkinson’s disease. Brain Imaging Behav. 2015;9(4):821–7.

16. Kunst J, Marecek R, Klobusíková P, Balážová Z, Anderková I, Nemcová-Elfmarková N, et al. Patterns of grey matter atrophy at different stages of Parkinson’s and Alzheimer’s diseases and relation to cognition. Brain Topogr. 2019;32(1):142–60.

17. Lu JS, Chen QY, Chen X, Li XH, Zhou Z, Liu Q, et al. Cellular and synaptic mechanisms for Parkinson’s disease-related chronic pain. Mol Pain. 2021;17:1744806921999025.

18. Jackson-Levis P, Przedborski S. Protocol for the MPTP mouse model of Parkinson’s disease. Nat Protoc. 2007;2(1):141–51.

19. Branchi I, D’Andrea I, Armida M, Carnevale D, Ajmone-Cat MA, Pezzola M, et al. Striatal 6-OHDA lesion in mice: investigating early neurochemical changes underlying Parkinson’s disease. Behav Brain Res. 2010;208(1):137–43.

20. Wu LJ, Kim SS, Li X, Zhang F, Zhuo M. Sexual attraction enhances glutamate transmission in mammalian anterior cingulate cortex. Mol Brain. 2009;2(1):9.

21. Koga K, Dascalzi G, Chen T, Ko H-G, Lu J, Li S, et al. Anterior cingulate dopamine turnover and behavior change in Parkinson’s disease. Brain Imaging Behav. 2015;9(4):821–7.

22. Kunst J, Marecek R, Klobusíková P, Balážová Z, Anderková I, Nemcová-Elfmarková N, et al. Patterns of grey matter atrophy at different stages of Parkinson’s and Alzheimer’s diseases and relation to cognition. Brain Topogr. 2019;32(1):142–60.

23. Li YY, Ko HG, Chen T, Dascalzi G, Koga K, Wang H, et al. Alleviating neuropathic pain hypersensitivity by inhibiting PKM in the anterior cingulate cortex. Science. 2010;330(6009):1400–4.

24. Koga K, Dascalzi G, Chen T, Ko H-G, Lu J, Li S, et al. Coexistence of two forms of LTD in ACC provides a synaptic mechanism for the interactions between anxiety and chronic pain. Neuron. 2015;85(2):377–89.

25. Gallagher CL, Bell B, Palotti M, Oh J, Christian BT, Okonkwo O, et al. Anterior cingulate dopamine turnover and behavior change in Parkinson’s disease. Brain Imaging Behav. 2015;9(4):821–7.

26. Kunst J, Marecek R, Klobusíková P, Balážová Z, Anderková I, Nemcová-Elfmarková N, et al. Patterns of grey matter atrophy at different stages of Parkinson’s and Alzheimer’s diseases and relation to cognition. Brain Topogr. 2019;32(1):142–60.

27. Lu JS, Chen QY, Chen X, Li XH, Zhou Z, Liu Q, et al. Cellular and synaptic mechanisms for Parkinson’s disease-related chronic pain. Mol Pain. 2021;17:1744806921999025.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.